ArticleScience advances2022
Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody.
Abstract read
In one paragraph
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- SARS-CoV-2 neutralizing antibody bebtelovimab - a systematic scoping review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses.Journal of virology · 2026Article
- Epistasis and background dependence in the evolution of Omicron variants of the SARS-CoV-2 spike protein.Molecular biology and evolution · 2026Article
- Article
- Engineering a multivalent antibody nanoparticle to overcome SARS-CoV-2 Omicron immune evasion.PLoS pathogens · 2025Article
- Optimizing the breadth of SARS-CoV-2-neutralizing antibodies in vivo and in silico.Human vaccines & immunotherapeutics · 2025Review
- Epistasis and background dependence in the evolution of Omicron variants of the SARS-CoV-2 Spike protein.bioRxiv : the preprint server for biology · 2025Article
- Separating selection from mutation in antibody language models.bioRxiv : the preprint server for biology · 2025Article
- Retrospective SARS-CoV-2 human antibody development trajectories are largely sparse and permissive.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Epitope mapping via in vitro deep mutational scanning methods and its applications.The Journal of biological chemistry · 2025Review
- Broadly potent spike-specific human monoclonal antibodies inhibit SARS-CoV-2 Omicron sub-lineages.Communications biology · 2024Article
- Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants.Viruses · 2024Review
- Article
- Cooperative and structural relationships of the trimeric Spike with infectivity and antibody escape of the strains Delta (B.1.617.2) and Omicron (BA.2, BA.5, and BQ.1).Journal of computer-aided molecular design · 2023Article
- Structural basis for broad neutralization of human antibody against Omicron sublineages and evasion by XBB variant.Journal of virology · 2023Article
- Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults.iScience · 2023Article
- Light chain of a public SARS-CoV-2 class-3 antibody modulates neutralization against Omicron.Cell reports · 2023Article
- Recognition determinants of improved HIV-1 neutralization by a heavy chain matured pediatric antibody.iScience · 2023Article
- Broadly neutralizing antibodies against COVID-19.Current opinion in virology · 2023Review
- Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants.Journal of virology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Sanjeev KumarICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India.ORCID 0000-0002-8181-3999
Anamika PatelDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0003-4760-9019
Lilin LaiDepartment of Pediatrics, Emory University School of Medicine, Emory University Atlanta, GA 30322, USA.
Chennareddy ChakravarthyDepartment of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0002-3937-5788
Rajesh ValanparambilDepartment of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.
Elluri Seetharami ReddyICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India.
Kamalvishnu GottimukkalaICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India.
Meredith E Davis-GardnerDepartment of Pediatrics, Emory University School of Medicine, Emory University Atlanta, GA 30322, USA.ORCID 0000-0002-6133-3613
Venkata Viswanadh EdaraDepartment of Pediatrics, Emory University School of Medicine, Emory University Atlanta, GA 30322, USA.ORCID 0000-0001-9321-7839
Susanne LindermanDepartment of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0003-3297-3774
Kaustuv NayakICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India.ORCID 0000-0002-7898-0294
Kritika DixitICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India.ORCID 0000-0002-7999-7274
Pragati SharmaICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India.ORCID 0000-0002-7554-6230
Prashant BajpaiICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India.ORCID 0000-0002-8443-9787
Vanshika SinghICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India.
Filipp FrankDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0001-8680-2757
Narayanaiah CheedarlaDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0001-6072-4383
Hans P VerkerkeDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Andrew S NeishDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0002-7090-0237
John D RobackDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0001-9952-2252
Grace MantusDepartment of Pediatrics, Emory University School of Medicine, Emory University Atlanta, GA 30322, USA.
Pawan Kumar GoelShaheed Hasan Khan Mewat Government Medical College, Haryana, India.
Manju RahiDivision of Epidemiology and Communicable Diseases, Indian Council of Medical Research, New Delhi-110 029, India.ORCID 0000-0003-0932-0935
Carl W DavisDepartment of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0002-6049-0684
Jens WrammertDepartment of Pediatrics, Emory University School of Medicine, Emory University Atlanta, GA 30322, USA.ORCID 0000-0002-1733-4424
Sucheta GodboleVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Amy R HenryVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Daniel C DouekVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Mehul S SutharDepartment of Pediatrics, Emory University School of Medicine, Emory University Atlanta, GA 30322, USA.ORCID 0000-0002-2686-8380
Rafi AhmedDepartment of Microbiology and Immunology, Emory University School of Medicine, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0002-9591-2621
Eric OrtlundDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0001-8855-3029
Amit SharmaICMR-National Institute of Malaria Research, Dwarka, New Delhi-110 077, India.ORCID 0000-0002-3305-0034
Kaja Murali-KrishnaICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India.ORCID 0000-0002-6275-1710
Anmol ChandeleICGEB-Emory Vaccine Center, International Center for Genetic Engineering and Biotechnology, New Delhi-110 067, India.ORCID 0000-0002-5702-7170
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3MMedical Scientist Training ProgramT32GM142617 · NIGMS · EMORY UNIVERSITY · PI Jason Yustein · 2022 to 2026
$7.0MNIGMS NIH HHS T32 GM008169NIGMS NIH HHS T32 GM142617
Abstract
In this study, by characterizing several human monoclonal antibodies (mAbs) isolated from single B cells of the COVID-19-recovered individuals in India who experienced ancestral Wuhan strain (WA.1) of SARS-CoV-2 during early stages of the pandemic, we found a receptor binding domain (RBD)-specific mAb 002-S21F2 that has rare gene usage and potently neutralized live viral isolates of SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta, and Omicron sublineages (BA.1, BA.2, BA.2.12.1, BA.4, and BA.5) with IC
Indexed as
COVID-19SARS-CoV-2Angiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, ViralEpitopesHumansNeutralization TestsSpike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, ViralEpitopesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.